Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NP800
- Development stage
- Preclinical
- Lead developer
- NETRIS Pharma
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
01
Overview
NP800 is a drug candidate currently in the discovery or preclinical stage of development by NETRIS Pharma for the treatment of glioblastoma. NETRIS Pharma is a clinical-stage biopharmaceutical company that specializes in developing anti-cancer therapeutic molecules, particularly monoclonal antibodies targeting dependence receptors and their ligands. While the company's lead candidate, NP137, targets netrin-1, the specific biological target and mechanism of action for NP800 have not been publicly disclosed. The drug is intended to address the high unmet medical need in glioblastoma, a primary brain tumor, by potentially inducing apoptosis in cancer cells through the interference of survival signaling pathways.
- Other names
- partially neutralized polyacrylate
Beyond the preview
Go deeper on NP800.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NP800.